As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Fennec Pharmaceuticals Inc. The largest reported stake is Rosalind Advisors, Inc.'s, at 9.6%. 11 filings are on record since November 13, 2025 (Schedule 13G/A, August 13, 2026).
Sell to companies like Fennec Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Orin Hirschman · Sole voting: 2,499,421 · Shared voting: 0 · Sole dispositive: 2,499,421 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-19
- · Reporting person: Solas Capital Management, LLC · Sole voting: 0 · Shared voting: 1,889,366 · Sole dispositive: 0 · Shared dispositive: 1,889,366 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Southpoint Master Fund, LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Rosalind Advisors, Inc. · Sole voting: 0 · Shared voting: 3,321,333 · Sole dispositive: 0 · Shared dispositive: 3,321,333 · SCHEDULE 13G/A, 2026-08-13
- · Holder: Solas Capital Management, LLC · Percent: 7.2% · SCHEDULE 13G/A
Fennec Pharmaceuticals Inc. has 11 Schedule 13D or 13G filings on record since 2025-11-13. 4 holders' latest filing reports 5% or more of common shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 9.6% | 3,321,333 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| 8.2% | 2,799,959 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 | |
| 7.1% | 2,499,421 | SCHEDULE 13G/A, 2026-10-19 | 2026-09-30 | |
| Solas Capital Management, LLC | 5.4% | 1,889,366 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Southpoint Master Fund, LP | 0% | 0 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Fennec Pharmaceuticals Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Fennec Pharmaceuticals Inc. and the records around it.
Fennec Pharmaceuticals Inc. elsewhere on the record
Companies that share a holder
- Southpoint Master Fund, LP also filed stake reports on 2 other companies: Dentsply Sirona Inc. (Aug 2026), Ibotta, Inc. (Aug 2025)
- Solas Capital Management, LLC also filed stake reports on 5 other companies: MAIA Biotechnology, Inc. (Aug 2026), Modular Medical, Inc. (Aug 2026), SANUWAVE Health, Inc. (Aug 2026)
- Rosalind Advisors, Inc. also filed stake reports on 11 other companies: DELCATH SYSTEMS, INC. (Oct 2026), FEMASYS INC (Aug 2026), REGENTIS BIOMATERIALS LTD. (Aug 2026)
Watch Fennec Pharmaceuticals Inc.
Get an email when Fennec Pharmaceuticals Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Fennec Pharmaceuticals Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Fennec Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Fennec Pharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | 0 | 3,321,333 | 0 | 3,321,333 | SCHEDULE 13G/A, 2026-08-13 |
| Salamon Steven A J | 66,666 | 3,188,001 | 66,666 | 3,188,001 | SCHEDULE 13G/A, 2026-08-13 |
| Aharon Gil | 66,666 | 3,188,001 | 66,666 | 3,188,001 | SCHEDULE 13G/A, 2026-08-13 |
| Rosalind Master Fund L.P. | 0 | 3,188,001 | 0 | 3,188,001 | SCHEDULE 13G/A, 2026-08-13 |
| Orin Hirschman | 2,499,421 | 0 | 2,499,421 | 0 | SCHEDULE 13G/A, 2026-10-19 |
| AIGH Capital Management LLC | 2,499,421 | 0 | 2,499,421 | 0 | SCHEDULE 13G/A, 2026-10-19 |
| Solas Capital Management, LLC | 0 | 1,889,366 | 0 | 1,889,366 | SCHEDULE 13G/A, 2026-08-14 |
| Frederick Tucker Golden | 0 | 1,889,366 | 0 | 1,889,366 | SCHEDULE 13G/A, 2026-08-14 |
| Southpoint Master Fund, LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Southpoint Capital Advisors LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Southpoint Capital Advisors LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Southpoint GP, LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Southpoint GP, LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| John S. Clark II | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Fennec Pharmaceuticals Inc. by CUSIP 31447P100 and gives its principal executive office as PO Box 13628, 68 TW Alexander Drive, Research Triangle Park, NC 27709 (SCHEDULE 13G/A, 2026-10-19).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-13 | Rosalind Advisors, Inc. | 7.5% | SCHEDULE 13G |
| 2026-01-14 | Southpoint Master Fund, LP | 8% | SCHEDULE 13G/A |
| 2026-02-11 | Rosalind Advisors, Inc. | 9.8% | SCHEDULE 13G/A |
| 2026-02-17 | Kam Lawrence | 8.2% | SCHEDULE 13G/A |
| 2026-04-28 | Orin Hirschman | 5.7% | SCHEDULE 13G |
| 2026-05-14 | Rosalind Advisors, Inc. | 8.8% | SCHEDULE 13G/A |
| 2026-05-15 | Solas Capital Management, LLC | 7.2% | SCHEDULE 13G/A |
| 2026-08-13 | Rosalind Advisors, Inc. | 9.6% | SCHEDULE 13G/A |
| 2026-08-14 | Southpoint Master Fund, LP | 0% | SCHEDULE 13G/A |
| 2026-08-14 | Solas Capital Management, LLC | 5.4% | SCHEDULE 13G/A |
| 2026-10-19 | Orin Hirschman | 7.1% | SCHEDULE 13G/A |
Questions about who owns Fennec Pharmaceuticals Inc.
Who owns Fennec Pharmaceuticals Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Fennec Pharmaceuticals Inc.: Rosalind Advisors, Inc. (9.6%, Schedule 13G/A, filed 2026-08-13), Kam Lawrence (8.2%, Schedule 13G/A, filed 2026-02-17), Orin Hirschman (7.1%, Schedule 13G/A, filed 2026-10-19) and Solas Capital Management, LLC (5.4%, Schedule 13G/A, filed 2026-08-14).
Who are the largest shareholders of Fennec Pharmaceuticals Inc.?
By the share each holder's latest filing reports, the largest holders of Fennec Pharmaceuticals Inc. on this page are Rosalind Advisors, Inc. (9.6%), Kam Lawrence (8.2%) and Orin Hirschman (7.1%).
When did Rosalind Advisors, Inc. buy into Fennec Pharmaceuticals Inc.?
The filings give report dates, not purchase dates. The earliest filing from Rosalind Advisors, Inc. on this page is the Schedule 13G, filed 2025-11-13, reporting 7.5%; its latest, Schedule 13G/A filed 2026-08-13, reports 9.6%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Fennec Pharmaceuticals Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.